# Gelteq Ltd (GELS)

Source page: https://stoqly.net/companies/gels

- **Ticker:** GELS (Nasdaq)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001920092
- **Latest annual report:** 20-F filed 2025-11-17 (https://www.sec.gov/Archives/edgar/data/1920092/000121390025111090/ea0265278-20f_gelteq.htm)
- **Data updated:** 2026-11-09

## What the company does

Gelteq develops edible gel products that carry medicines, nutrients and other ingredients for people and animals. Its white-label products are sold by other companies under their own brands. The product range covers pets, sports nutrition, pharmaceuticals, over-the-counter products and nutraceuticals, such as vitamins and supplements. The gels can combine multiple ingredients in one measured dose and are designed to mask unpleasant tastes and make products easier to swallow. Gelteq also licenses its gel technology to companies that develop, manufacture and sell products in their own markets.

Gelteq focuses on licensing its technology and making existing products under license. Its products serve pet care, sports, pharmaceutical, over-the-counter and nutraceutical markets. Sports gels contain electrolytes and carbohydrates; pet products address needs such as joint health, coat quality and digestion. Customers named include sports organizations PacificPine Tennis Limited, PacificPine Football Limited and PacificPine Golf Limited, as well as supplement company Healthy Extracts Inc. Gelteq works with partners on product development and sales, including WPIC Marketing and Technologies Limited for distribution in the Asia Pacific region.

Gelteq’s gels use food-grade ingredients and can be adjusted for different textures and release rates. It develops formulations and works with manufacturers to produce products, while also seeking licensees to use its technology. Its research partnership with Monash University supports testing of gel formulations. Gelteq is based in Australia, with its principal place of business in Clayton, Victoria.

## Key figures

- **Last close:** $0.38 on 2026-11-13 (−0.13% on the day)
- **Market cap:** $3.5M
- **EPS, trailing 12 months:** −$0.47
- **Revenue (FY2025):** $0.1M
- **Gross margin:** 30.3%
- **Operating margin:** −3,318.0%
- **Net margin:** −4,012.2%
- **Free cash flow:** −$3.6M
- **Free cash flow margin:** −3,335.6%
- **Return on invested capital:** −21.9%
- **Return on equity:** −42.2%
- **Net debt:** $2.5M
- **Change in share count:** +14.2%
- **Piotroski F-score:** 2/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/gels/figures.csv

| US$ millions | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|
| Revenue | 0 | — | 0 |
| Operating income | -2 | -2 | -4 |
| Net income | -2 | -2 | -4 |
| Diluted EPS (US$) | -0.30 | -0.29 | -0.47 |
| Operating cash flow | -1 | -1 | -4 |
| Free cash flow | -1 | -1 | -4 |
| Cash | 0 | 0 | 0 |
| Debt and leases | 2 | 3 | 3 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.